



INSTITUT  
**JULES BORDET**  
INSTITUUT

**Clinical Trial Title :** An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in subjects with brain metastasis of advanced HER2 positive breast cancer

**EudraCT Number :** 2020-000824-21

**Protocol Number :** IJB-NERABRAIN-ODN-007

**Study name :** NERABRAIN

**NO or PARTIAL RESULTS FOR THIS TRIAL**

**(I) Accrual**

- The trial is terminated before any subject was recruited.
- The trial is terminated whereas \_\_\_\_\_ subjects/ \_\_\_\_\_ were recruited.

**(II) Reason(s)**

- The positive opinion by the Ethics Committee in charge of the trial is not granted or is irrevocably revoked.
- The authorisation by the Competent Authority of the Member State concerned in charge of the trial is not granted or is irrevocably revoked.
- The sponsor became or was declared insolvent or a petition in bankruptcy has been filed against it or it is dissolved.
- Early end of the scientific collaboration with one or more partners.
- Early termination due to safety.
- Discontinuation or change of the strategic direction of the development of the medicinal product(s) that the sponsor wanted to study.
- Trial logistics or limited trial population, as defined by the inclusion/exclusion criteria, leading to a poor recruitment.
- Publication of other clinical trials which changed the therapeutic landscape and rendered our trial design obsolete.
- Publication of other clinical trials already demonstrating the clinical interest of our trial and rendered our trial obsolete.

Rue Meylemeersch N°90, 1070 Anderlecht, Belgique  
T + 32 (0)2 541 31 11, F + 32 (0)2 541 35 06, BELFIUS 091-0097278-16, [www.bordet.be](http://www.bordet.be)

Institut Jules Bordet, Association Hospitalière de Bruxelles régie par la loi du 8 juillet 1976  
Jules Bordet Instituut, Ziekenhuisvereniging van Brussel onderworpen aan de wet van 8 juli 1976